Literature DB >> 8471342

Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.

J Verweij, D Gandia, A S Planting, G Stoter, J P Armand.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471342     DOI: 10.1016/s0959-8049(05)80369-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  6 in total

1.  Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Authors:  Stefan R Vink; Jan H M Schellens; Wim J van Blitterswijk; Marcel Verheij
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 2.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

Authors:  J M Terwogt; I A Mandjes; H Sindermann; J H Beijnen; W W ten Bokkel Huinink
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 4.  Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.

Authors:  Temmy Sunyoto; Julien Potet; Marleen Boelaert
Journal:  BMJ Glob Health       Date:  2018-05-03

Review 5.  Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.

Authors:  Rajesh Kumar; Seetha Harilal; Sheeba Varghese Gupta; Jobin Jose; Della Grace Thomas Parambi; Md Sahab Uddin; Muhammad Ajmal Shah; Bijo Mathew
Journal:  Eur J Med Chem       Date:  2019-08-08       Impact factor: 6.514

6.  Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture's Pathogen Box.

Authors:  Gina Wall; Natalia Herrera; José L Lopez-Ribot
Journal:  J Fungi (Basel)       Date:  2019-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.